<DOC>
	<DOCNO>NCT00210535</DOCNO>
	<brief_summary>The primary purpose study evaluate effectiveness safety topiramate compare placebo prevention migraine attack child ( 12 17 year age ) .</brief_summary>
	<brief_title>A Study Effectiveness Safety Topiramate Prevention Migraine Attacks Children</brief_title>
	<detailed_description>This outpatient , randomize , double-blind , placebo-controlled study evaluate effectiveness 2 dosage topiramate ( 50 100 milligrams/day ) compare placebo prevention migraine attack child 12 17 year age . The study compose 3 phase : pretreatment , double-blind treatment 4 month ( 16 week ) , posttreatment . During study , patient maintain headache medication record document follow : occurrence duration headache ; severity headache pain ; whether headache pulsating aggravate physical activity ; associate symptom , nausea , vomit , photophobia , phonophobia , abdominal pain ; medication take relieve headache pain symptom . Assessment efficacy include percent reduction frequency monthly migraine attack last 12 week double-blind treatment phase compare prospective BL period . In addition , percent reduction ( ) average monthly migraine day , ( b ) average monthly headache day , ( c ) monthly migraine rate , last 12 week double-blind treatment phase compare pretreatment phase assess . Safety assessment include incidence adverse event , measurement vital sign ( pulse , blood pressure , oral temperature ) , result pregnancy test , physical neurologic examination , clinical laboratory test ( hematology , biochemistry , urinalysis ) , monitor visual ocular disturbance , heat intolerance , renal urinary disturbance , depression rash . The study hypothesis percent reduction frequency monthly ( 28-day ) migraine attack ( use 48-hour rule ) prospective baseline period ( pretreatment phase ) last 12 week double-blind phase significantly well topiramate group placebo group . Topiramate tablet ( 25 milligram ) placebo , begin 25mg daily ( Week 1 ) , increase twice daily total 50mg 100mg ( Week 4 ) . Maximum dosage topiramate ( placebo ) continue next 12 week . Dosage may reduce investigator 's discretion .</detailed_description>
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Vascular Headaches</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<criteria>History migraine ( without aura ) conform International Headache Society ( IHS ) criterion pediatric subject &gt; =6 month prior screen Requires migraine prophylactic therapy , previously treat prevent attack , unsatisfactory response therapy Experienced average 3 12 migraine attack 14 headache day per month 3 month prior study Females must sexually abstinent , surgically sterile , use adequate contraceptive measure , negative pregnancy test study Currently take previously unable tolerate topiramate , previously fail therapy topiramate migraine prophylaxis Has mixed headache unable distinguish migraine headache type Overuses pain medication specific agent abortive treatment migraine attack Has body mass index ( BMI ) great 40 weighs 200 pound , markedly underweight ( 5th percentile ) age</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Topiramate</keyword>
	<keyword>Migraine</keyword>
	<keyword>Migraine headache</keyword>
	<keyword>Migraine prevention</keyword>
	<keyword>Pediatric</keyword>
</DOC>